Syngene unveils platform for rapid, enhanced protein production

"Syngene sees biologics as a key driver of future growth and we are committed to investing in cutting-edge technology to achieve reliability, precision and speed for clients. By combining Syngene's skills and experience with ExcellGene's best-in-class cell line development technology, we can expedite getting molecules to market for the people and patients who need them," said Alex Del Priore, Senior Vice President, Manufacturing Services, Syngene International.

"High yield manufacturing is a multifactorial exercise that starts with transfections and an optimised cell host. We are obviously delighted to partner with and to contribute to Syngene's process development and manufacturing capabilities. This will leverage our technology and our cells (CHOExpress) for the benefit of their extensive client base. At ExcellGene, we pride ourselves in having studied the profound challenges in DNA transfer to cultivated cells for decades and linked insights from such studies to their phenotypes and use in manufacturing. We are delighted that our work, combined with the talent and expertise of the Syngene team, will directly benefit patients around the world", said Maria J. and Florian M. Wurm, Cofounders and Managers, ExcellGene

The new platform streamlines clone selection and enhances operational productivity. It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins. This versatility facilitates integration with both perfusion and fed-batch manufacturing processes.